Tumor-associated antigen-HLA complex (TAA-HLA) (TAA-HLA)

The tumor-associated antigen-HLA (TAA-HLA) complex is a critical molecular target in cancer immunotherapy, representing the presentation of intracellular protein fragments on the cell surface for T-cell recognition. These complexes are formed when degraded cellular proteins, including mutated neoantigens or overexpressed self-antigens, are loaded onto Human Leukocyte Antigen (HLA) Class I or II molecules and transported to the plasma membrane (Source: Nature Reviews Cancer, 2021). T-cell receptors (TCRs) specifically interact with these peptide-MHC structures, allowing the immune system to identify and eliminate malignant cells (Source: NIH/NCI). Therapeutic interventions such as TCR-engineered T-cell (TCR-T) therapies and bispecific T-cell engagers are designed to provide high-affinity recognition of these specific complexes (Source: Journal of Hematology & Oncology, 2023). This targeting strategy is particularly valuable because it enables the recognition of internal oncogenic drivers that are otherwise inaccessible to conventional antibody-based therapies (Source: Frontiers in Immunology, 2022). However, the success of these treatments is highly dependent on the patient's specific HLA genotype and the consistent expression of the target antigen by the tumor (Source: Science, 2019). Notable challenges include the potential for off-target toxicity if the targeted peptide sequence is shared by proteins in healthy tissues (Source: PubMed, 2020). Additionally, tumors may develop resistance through the downregulation of HLA molecules, effectively hiding the antigens from T-cell detection (Source: Cell, 2021).

Other names

Peptide-HLA complexpMHC complexTumor-specific antigen-HLA complexNeoantigen-HLA complexAntigen-HLA complex

Therapeutic agents specifically recognize and bind the peptide-HLA complex on the tumor cell surface, triggering T-cell activation and directed cytotoxicity against the cancer cell.